# Xunbaihui Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xunbaihui-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.bioxbh.com
- Total disclosed funding: $2.9M
- Latest round: Series B (Oct 14, 2021)
- Investors on record: 6

## About

Founded in 2016 and based in Shanghai, China, Xunbaihui Biotechnology Co., Ltd. is a medical services company that focuses on cancer diagnosis and treatment. The founder of the company, Xiaole Liu, is a tenured professor at Harvard University and Professor of the Center for Epigenetics at Dana Farber Cancer Institute. The company was recognized as a national high-tech enterprise and the list of science and technology-based small and medium-sized enterprises. In October 2021, it closed Serie B funding led by Coatue Management, with participation from returning investors IDG Capital, Watson Capital, Linear Capital, along with the participation from other new investor 3W Investment.

Xunbaihui Biotechnology Co., Ltd.'s main product category are oncology antibody drugs. Products within include XBH25, XBH62, and XBH82. It also has the GV20 Genomics Platform and GV20 Artificial Intelligence Platform, which are used for tumor immune target tracking and cancer antibody drug discovery and development, such as CRISPR and Cas9 high-throughput screening services. The company's products have served cancer patients, pharmaceutical companies and research institutions.

## Funding rounds

- Series B, Oct 14, 2021 — IDG Capital, Coatue Management, Linear Capital Partners, Watson Investment, 3W Investment
- Angel, Oct 8, 2018, $2.9M — IDG Capital, Linear Capital, Watson Investment

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Angel, Series B
- Linear Capital (https://capitalatlas.ai/funds/linear-capital) — Angel
- Watson Investment — Angel, Series B
- Coatue Management (https://capitalatlas.ai/funds/coatue-management) — Series B
- Linear Capital Partners — Series B
- 3W Investment — Series B
